{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:28:04Z","timestamp":1721176084774},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,16]]},"DOI":"10.7759\/cureus.64637","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T09:32:00Z","timestamp":1721122320000},"source":"Crossref","is-referenced-by-count":0,"title":["Determining the Treatment Strategy for Refractory Ulcerative Colitis Using Prostaglandin E-major Urinary Metabolite (PGE-MUM) Measurement"],"prefix":"10.7759","author":[{"given":"Ryosuke","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Honma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab112","article-title":"Ecco topical review: refractory inflammatory bowel disease","volume":"15","author":"Raine T","year":"2021","unstructured":"Raine T, Verstockt B, Kopylov U, et al.. Ecco topical review: refractory inflammatory bowel disease. J Crohns Colitis. 2021, 15:1605-20. 10.1093\/ecco-jcc\/jjab112","journal-title":"J Crohns Colitis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0415-0","article-title":"Targeting immune cell circuits and trafficking in inflammatory bowel disease","volume":"20","author":"Neurath MF","year":"2019","unstructured":"Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol. 2019, 20:970-9. 10.1038\/s41590-019-0415-0","journal-title":"Nat Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.103017","article-title":"The influence of cytokines on the complex pathology of ulcerative colitis","volume":"21","author":"Nakase H","year":"2022","unstructured":"Nakase H, Sato N, Mizuno N, Ikawa Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev. 2022, 21:103017. 10.1016\/j.autrev.2021.103017","journal-title":"Autoimmun Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000441665","article-title":"Prostaglandin E-major urinary metabolite as a biomarker for inflammation in ulcerative colitis: prostaglandins revisited","volume":"93","author":"Arai Y","year":"2016","unstructured":"Arai Y, Matsuura T, Matsuura M, Fujiwara M, Okayasu I, Ito S, Arihiro S. Prostaglandin E-major urinary metabolite as a biomarker for inflammation in ulcerative colitis: prostaglandins revisited. Digestion. 2016, 93:32-9. 10.1159\/000441665","journal-title":"Digestion"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder KW","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987, 317:1625-9. 10.1056\/NEJM198712243172603","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.05.029","article-title":"Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study","volume":"133","author":"Turner D","year":"2007","unstructured":"Turner D, Otley AR, Mack D, et al.. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007, 133:423-32. 10.1053\/j.gastro.2007.05.029","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001477","article-title":"Prostaglandin E-major urinary metabolite as a biomarker for pediatric ulcerative colitis activity","volume":"64","author":"Hagiwara SI","year":"2017","unstructured":"Hagiwara SI, Okayasu I, Fujiwara M, et al.. Prostaglandin E-major urinary metabolite as a biomarker for pediatric ulcerative colitis activity. J Pediatr Gastroenterol Nutr. 2017, 64:955-61. 10.1097\/MPG.0000000000001477","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxz021","article-title":"Molecular mechanisms underlying prostaglandin E2-exacerbated inflammation and immune diseases","volume":"31","author":"Tsuge K","year":"2019","unstructured":"Tsuge K, Inazumi T, Shimamoto A, Sugimoto Y. Molecular mechanisms underlying prostaglandin E2-exacerbated inflammation and immune diseases. Int Immunol. 2019, 31:597-606. 10.1093\/intimm\/dxz021","journal-title":"Int Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D'Haens G","year":"2023","unstructured":"D'Haens G, Dubinsky M, Kobayashi T, et al.. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023, 388:2444-55. 10.1056\/NEJMoa2207940","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otae001","article-title":"Association of bowel urgency with quality-of-life measures in patients with moderately-to-severely active ulcerative colitis: results from Phase 3 Lucent-1 (induction) and Lucent-2 (Maintenance) studies","volume":"6","author":"Long MD","year":"2024","unstructured":"Long MD, Schreiber S, Hibi T, et al.. Association of bowel urgency with quality-of-life measures in patients with moderately-to-severely active ulcerative colitis: results from Phase 3 Lucent-1 (induction) and Lucent-2 (Maintenance) studies. Crohns Colitis 360. 2024, 6:otae001. 10.1093\/crocol\/otae001","journal-title":"Crohns Colitis 360"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua DJ","year":"2003","unstructured":"Cua DJ, Sherlock J, Chen Y, et al.. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003, 421:744-8. 10.1038\/nature01355","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16521","article-title":"Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies","volume":"34","author":"Strober B","year":"2020","unstructured":"Strober B, Menter A, Leonardi C, et al.. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol. 2020, 34:2830-8. 10.1111\/jdv.16521","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/268921-determining-the-treatment-strategy-for-refractory-ulcerative-colitis-using-prostaglandin-e-major-urinary-metabolite-pge-mum-measurement","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T09:32:03Z","timestamp":1721122323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/268921-determining-the-treatment-strategy-for-refractory-ulcerative-colitis-using-prostaglandin-e-major-urinary-metabolite-pge-mum-measurement"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.64637","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,16]]}}}